首页 > 最新文献

Journal of Pharmacy Practice and Research最新文献

英文 中文
Hospital-initiated post-discharge medication reviews in Australia: expert opinion on the barriers and enablers to implementation 澳大利亚医院发起的出院后药物审查:关于实施障碍和促进因素的专家意见
IF 2.1 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2022-10-06 DOI: 10.1002/jppr.1832
Manya Angley BPharm, PhD, AACPA, AdvPracPharm, FSHP, FPS, Deirdre Criddle BPharm, GradDipPharm, AACPA, AdvPracPharm, FPS, MSHP, MRPharmS, Deborah Rigby BPharm, GradDipClinPharm, AdvPracPharm, AACPA, FPS, FSHPA, FACP, FASCP, FAICD, Rohan A. Elliott BPharm, BPharmSc (Hons), MClinPharm, FSHP, PhD, Katie Phillips BPharm (Hons), Grad Cert Pharmacy Practice, AACPA, MSHP, Jonathan Penm BPharm (Hons), PhD, GradCert (Higher Ed), FFIP, FSHP, FHEA, Janet K. Sluggett BPharm (Hons), PhD, GradDipClinEpid, AACPA, FSHP, GAICD, Joy Gailer BPharm, DipHospPharm, BCPS, AdvPracPharm, FPS, MSHP, Horst Thiele DipPharm, MSHP, Amy T. Page PhD, BHealth Sci, BPharm, Grad Dip Biostatistics, Grad Cert Health Prof Ed, Grad Cert Pharm Pract, MClinPharm, AACPA, AdvPracPharm, FPS, Carly Pauw BPharm, MSHP, Sarah Gillespie BPharm, AACPA, MSHP, MPS, Sepehr Shakib MBBS, PhD, FRACP, Jerry Yik BPharm MPubPol

Medication-related harm can occur during transitions of care. Revised Home Medicines Review (HMR) and Residential Medication Management Review (RMMR) program rules were published in April 2020 which allowed provision for some hospital medical practitioners to refer at-risk patients for medication review. In turn, the Society of Hospital Pharmacists of Australia's (SHPA's) Transitions of Care and Primary Care Leadership Committee developed a framework to support hospitals facilitating Hospital-Initiated Medication Reviews (HIMRs) via three pathways: HMR, RMMR, and Hospital Outreach Medication Review. Following the compilation of draft barriers and enablers to implementation of the SHPA HIMR framework, refinement occurred after broad consultation with hospital- and primary care-based pharmacists with transitions of care experience. The finalised list of barriers and enablers can inform broadscale implementation of the SHPA HIMR framework to reduce medication-related harm when high-risk patients transition from hospital to primary care and aged care.

与药物有关的伤害可能发生在护理的过渡阶段。修订后的家庭药物审查(HMR)和住院药物管理审查(RMMR)计划规则于2020年4月发布,允许一些医院医生推荐有风险的患者进行药物审查。反过来,澳大利亚医院药剂师协会(SHPA)的护理过渡和初级保健领导委员会制定了一个框架,以支持医院通过三种途径促进医院发起的药物审查(HIMRs): HMR, RMMR和医院外展药物审查。在编制了实施SHPA HIMR框架的障碍和促进因素草案之后,在与医院和初级保健的药剂师进行了广泛的咨询后,对其进行了改进。最终确定的障碍和促进因素清单可以为SHPA HIMR框架的广泛实施提供信息,以减少高风险患者从医院转向初级保健和老年保健时的药物相关伤害。
{"title":"Hospital-initiated post-discharge medication reviews in Australia: expert opinion on the barriers and enablers to implementation","authors":"Manya Angley BPharm, PhD, AACPA, AdvPracPharm, FSHP, FPS,&nbsp;Deirdre Criddle BPharm, GradDipPharm, AACPA, AdvPracPharm, FPS, MSHP, MRPharmS,&nbsp;Deborah Rigby BPharm, GradDipClinPharm, AdvPracPharm, AACPA, FPS, FSHPA, FACP, FASCP, FAICD,&nbsp;Rohan A. Elliott BPharm, BPharmSc (Hons), MClinPharm, FSHP, PhD,&nbsp;Katie Phillips BPharm (Hons), Grad Cert Pharmacy Practice, AACPA, MSHP,&nbsp;Jonathan Penm BPharm (Hons), PhD, GradCert (Higher Ed), FFIP, FSHP, FHEA,&nbsp;Janet K. Sluggett BPharm (Hons), PhD, GradDipClinEpid, AACPA, FSHP, GAICD,&nbsp;Joy Gailer BPharm, DipHospPharm, BCPS, AdvPracPharm, FPS, MSHP,&nbsp;Horst Thiele DipPharm, MSHP,&nbsp;Amy T. Page PhD, BHealth Sci, BPharm, Grad Dip Biostatistics, Grad Cert Health Prof Ed, Grad Cert Pharm Pract, MClinPharm, AACPA, AdvPracPharm, FPS,&nbsp;Carly Pauw BPharm, MSHP,&nbsp;Sarah Gillespie BPharm, AACPA, MSHP, MPS,&nbsp;Sepehr Shakib MBBS, PhD, FRACP,&nbsp;Jerry Yik BPharm MPubPol","doi":"10.1002/jppr.1832","DOIUrl":"10.1002/jppr.1832","url":null,"abstract":"<p>Medication-related harm can occur during transitions of care. Revised Home Medicines Review (HMR) and Residential Medication Management Review (RMMR) program rules were published in April 2020 which allowed provision for some hospital medical practitioners to refer at-risk patients for medication review. In turn, the Society of Hospital Pharmacists of Australia's (SHPA's) Transitions of Care and Primary Care Leadership Committee developed a framework to support hospitals facilitating Hospital-Initiated Medication Reviews (HIMRs) via three pathways: HMR, RMMR, and Hospital Outreach Medication Review. Following the compilation of draft barriers and enablers to implementation of the SHPA HIMR framework, refinement occurred after broad consultation with hospital- and primary care-based pharmacists with transitions of care experience. The finalised list of barriers and enablers can inform broadscale implementation of the SHPA HIMR framework to reduce medication-related harm when high-risk patients transition from hospital to primary care and aged care.</p>","PeriodicalId":16795,"journal":{"name":"Journal of Pharmacy Practice and Research","volume":"52 6","pages":"446-453"},"PeriodicalIF":2.1,"publicationDate":"2022-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44798004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Managing chronic obstructive pulmonary disease in primary care: clinical characteristics of patients receiving inhaled corticosteroids 初级保健中慢性阻塞性肺疾病的管理:接受吸入皮质类固醇患者的临床特征
IF 2.1 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2022-10-04 DOI: 10.1002/jppr.1835
Madisyn Strain PharmD, BCPS, BCACP, Kaci Boehmer PharmD, BCACP, CDCES, Justin Usery PharmD, BCPS
Inhaled corticosteroid (ICS) therapy in patients with chronic obstructive pulmonary disease (COPD) has been associated with a variety of unfavourable effects, including increased risk of pneumonia, and is only recommended if specific characteristics are present to ensure patients derive the most benefit.
慢性阻塞性肺疾病(COPD)患者吸入皮质类固醇(ICS)治疗与多种不良反应相关,包括肺炎风险增加,仅在存在特定特征以确保患者获得最大益处的情况下才推荐使用。目的:本研究的主要目的是评估在一个学术医疗中心的两个初级保健诊所使用ICS治疗COPD的患者的临床特征。次要目的是检查提供者的评估和障碍,以处方模式符合门诊护理设置的指导方针。方法在美国阿肯色州的一个学术医疗中心的两个初级保健诊所进行了为期24个月的回顾性研究,重点研究了给予ICS维持治疗的成年患者。根据2019年1月1日至2020年12月31日指示COPD的疾病分类第十版临床修改(ICD-10-CM)代码对每个诊所内的个体进行鉴定。还需要肺量测定来确认诊断。结果在确定的189例独特患者中,有100例符合临床特征审查的条件。所有患者均接受ICS联合长效β受体激动剂(LABA)治疗,55%的患者同时接受长效毒蕈碱拮抗剂(LAMA)治疗。此外,32%的患者在过去一年内因慢性阻塞性肺病加重而就诊或住院。大约47%和36%的患者分别有肺炎史和嗜酸性粒细胞计数100个细胞/mcL。通过与每个诊所的提供者进行公开讨论,确定了遵循指南的障碍,其中包括诊所环境中缺乏现成的资源,电子病历中临床工具的次优识别以及可选择的指南偏好。研究中评估的一小部分患者被发现具有提示强大ICS益处的临床特征,因为这些治疗要么由于低血嗜酸性粒细胞计数或加重率(分别为80%和68%)而缺乏疗效,要么增加了该人群继发于先前肺炎诊断的危害风险(47%)。
{"title":"Managing chronic obstructive pulmonary disease in primary care: clinical characteristics of patients receiving inhaled corticosteroids","authors":"Madisyn Strain PharmD, BCPS, BCACP,&nbsp;Kaci Boehmer PharmD, BCACP, CDCES,&nbsp;Justin Usery PharmD, BCPS","doi":"10.1002/jppr.1835","DOIUrl":"10.1002/jppr.1835","url":null,"abstract":"Inhaled corticosteroid (ICS) therapy in patients with chronic obstructive pulmonary disease (COPD) has been associated with a variety of unfavourable effects, including increased risk of pneumonia, and is only recommended if specific characteristics are present to ensure patients derive the most benefit.","PeriodicalId":16795,"journal":{"name":"Journal of Pharmacy Practice and Research","volume":"52 6","pages":"438-445"},"PeriodicalIF":2.1,"publicationDate":"2022-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42289094","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Perioperative medication management for older people 老年人围手术期用药管理
IF 2.1 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2022-10-02 DOI: 10.1002/jppr.1834
Samuel Johnson MBBS, Cilla Haywood MBBS, PhD, FRACP

The average age of surgical candidates is increasing with the ageing population worldwide. Major surgery in older patients is associated with a significant risk of complications due to physiologic changes occurring with ageing and individual patient factors such as frailty, polypharmacy, and multimorbidity. Periodic medication review should be part of the routine management of all older patients, with the perioperative period presenting an opportune time for this review. Regular medications may need short-term modification during the surgical period. Medications implicated in increasing risk of inducing or worsening delirium should be identified and withdrawal considered ahead of time. Perioperative commencement of medication aimed at reducing risk of other complications, including cardiovascular events, should be considered on an individual basis, analysing risks and benefits. Comprehensive medication review and careful planning through the perioperative period may enhance the prospects of recovery and reduce morbidity and mortality for older surgical patients.

外科候选人的平均年龄随着全球人口老龄化而增加。老年患者的大手术与并发症的显著风险相关,这是由于随着年龄的增长和个体患者因素(如虚弱、多种药物和多种疾病)而发生的生理变化。定期用药复查应成为所有老年患者常规管理的一部分,围手术期是进行此类复查的合适时机。常规药物在手术期间可能需要短期调整。涉及增加诱导或加重谵妄风险的药物应确定并提前考虑停药。围手术期开始用药旨在降低其他并发症的风险,包括心血管事件,应考虑在个人的基础上,分析风险和收益。全面的用药回顾和围手术期的精心规划可以提高老年外科患者的康复前景,降低发病率和死亡率。
{"title":"Perioperative medication management for older people","authors":"Samuel Johnson MBBS,&nbsp;Cilla Haywood MBBS, PhD, FRACP","doi":"10.1002/jppr.1834","DOIUrl":"10.1002/jppr.1834","url":null,"abstract":"<p>The average age of surgical candidates is increasing with the ageing population worldwide. Major surgery in older patients is associated with a significant risk of complications due to physiologic changes occurring with ageing and individual patient factors such as frailty, polypharmacy, and multimorbidity. Periodic medication review should be part of the routine management of all older patients, with the perioperative period presenting an opportune time for this review. Regular medications may need short-term modification during the surgical period. Medications implicated in increasing risk of inducing or worsening delirium should be identified and withdrawal considered ahead of time. Perioperative commencement of medication aimed at reducing risk of other complications, including cardiovascular events, should be considered on an individual basis, analysing risks and benefits. Comprehensive medication review and careful planning through the perioperative period may enhance the prospects of recovery and reduce morbidity and mortality for older surgical patients.</p>","PeriodicalId":16795,"journal":{"name":"Journal of Pharmacy Practice and Research","volume":"52 5","pages":"391-401"},"PeriodicalIF":2.1,"publicationDate":"2022-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jppr.1834","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45302932","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Response from Authors: a benchmarking scoping review of research output from hospital pharmacy departments in Australia 作者回应:对澳大利亚医院药学部门的研究成果进行基准范围审查
IF 2.1 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2022-09-19 DOI: 10.1002/jppr.1833
Jonathan Penm BPharm (Hons), PhD, GradCert (Higher Ed), Sujita Narayan PhD, Jan-Willem Alffenaar PharmD, PhD, Jacinta L. Johnson BPharm (Hons), PhD, AdvPracPharm, Sanja Mirkov BPharm, PGDipPH, Amy T. Page PhD, MClinPharm, GradDipBiostat, GCertHProfEd, MAACP, GStat, FPS, AdvPracPharm, Lisa G. Pont BSc, BPharm, MSc(Epi), PhD, Asad E. Patanwala PharmD, MPH

To the Editor,

We thank Elliott et al.1 and Misko et al.2 for their feedback on our recent scoping review.3 They both provided valuable feedback for future benchmarking studies. We acknowledge that these limitations may impact state or territory-based benchmarking but reinforce that the national benchmarking offered by our paper appears useful for such sites to compare against.

Amy Page is an Editorial Board member of the Journal of Pharmacy Practice and Research and a co-author of this article. To minimise bias, she was excluded from all editorial decision-making related to the acceptance of this article for publication.

All listed authors comply with the Journal's authorship policy.

No ethics approval was required for this letter to the editor.

感谢编辑Elliott等人。1和Misko等人。他们对我们最近的范围审查的反馈他们都为未来的基准研究提供了宝贵的反馈。我们承认这些限制可能会影响以州或地区为基础的基准,但我们强调,我们的论文提供的国家基准对这些网站进行比较似乎是有用的。Amy Page是《药学实践与研究》杂志的编辑委员会成员,也是本文的合著者。为了尽量减少偏见,她被排除在与接受这篇文章发表有关的所有编辑决策之外。所有列出的作者都遵守《华尔街日报》的作者身份政策。这封写给编辑的信不需要伦理审批。
{"title":"Response from Authors: a benchmarking scoping review of research output from hospital pharmacy departments in Australia","authors":"Jonathan Penm BPharm (Hons), PhD, GradCert (Higher Ed),&nbsp;Sujita Narayan PhD,&nbsp;Jan-Willem Alffenaar PharmD, PhD,&nbsp;Jacinta L. Johnson BPharm (Hons), PhD, AdvPracPharm,&nbsp;Sanja Mirkov BPharm, PGDipPH,&nbsp;Amy T. Page PhD, MClinPharm, GradDipBiostat, GCertHProfEd, MAACP, GStat, FPS, AdvPracPharm,&nbsp;Lisa G. Pont BSc, BPharm, MSc(Epi), PhD,&nbsp;Asad E. Patanwala PharmD, MPH","doi":"10.1002/jppr.1833","DOIUrl":"10.1002/jppr.1833","url":null,"abstract":"<p>To the Editor,</p><p>We thank Elliott et al.<span><sup>1</sup></span> and Misko et al.<span><sup>2</sup></span> for their feedback on our recent scoping review.<span><sup>3</sup></span> They both provided valuable feedback for future benchmarking studies. We acknowledge that these limitations may impact state or territory-based benchmarking but reinforce that the national benchmarking offered by our paper appears useful for such sites to compare against.</p><p>Amy Page is an Editorial Board member of the <i>Journal of Pharmacy Practice and Research</i> and a co-author of this article. To minimise bias, she was excluded from all editorial decision-making related to the acceptance of this article for publication.</p><p>All listed authors comply with the <i>Journal's</i> authorship policy.</p><p>No ethics approval was required for this letter to the editor.</p>","PeriodicalId":16795,"journal":{"name":"Journal of Pharmacy Practice and Research","volume":"52 5","pages":"406-407"},"PeriodicalIF":2.1,"publicationDate":"2022-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jppr.1833","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48711928","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Improving medicine information on discharge summaries through implementation of a reconciliation-based intervention 通过实施以和解为基础的干预措施,改善出院总结的医学信息
IF 2.1 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2022-09-16 DOI: 10.1002/jppr.1828
Anna Nguyen BPharm (Hons), GradCertPharmPrac, Stephanie Gibson BPharm (Hons), MClinPharm, Paul Wembridge BPharm (Hons), MClinPharm

The handover of medication-related information at the point of discharge often occurs via the discharge summary (DS), although these frequently contain errors. We aimed to investigate whether an intern pharmacist reviewing the medication details in discharge summaries (DSs), reconciling them with the discharge prescription and pointing out any discrepancies with the medical staff would reduce the rate of medication errors. The intervention was retrospectively reviewed by comparing medication information on the DS with the discharge prescription (considered the ‘source of truth’). Error rates on the DS were compared to a control group of patients discharged over a different 2-week period from the same ward. A modified APINCH (Antimicrobials, Potassium and other electrolytes, Insulin, Narcotics and other sedatives, Chemotherapeutic agents, Heparin and other anticoagulants, Systems) classification system was used to identify high-risk errors. The time taken to perform the intervention was measured and details of any recommendations collected. The study included 22 intervention patients and 31 control patients. Patients who received the intervention were less likely to have one or more medication errors on their DS (any: 4% vs 84%, p < 0.01; high-risk: 0% vs 29%, p < 0.01). The intern pharmacist made a total of 77 recommendations during the intervention. Six recommendations (8%) related to high-risk medications. The median time required to undertake the first review was 4 min, and the second review took 1 min. In conclusion, we found a reconciliation-based intervention involving an intern pharmacist could reduce the rate of medication errors on DSs.

出院时药物相关信息的移交通常通过出院摘要(DS)进行,尽管这些摘要经常包含错误。本研究旨在探讨实习药师审阅出院摘要(DSs)中的用药细节,与出院处方核对,并指出与医务人员的差异是否会降低用药错误率。通过比较DS上的药物信息和出院处方(被认为是“事实来源”)对干预进行回顾性评价。将DS的错误率与同一病房在不同两周内出院的对照组患者进行比较。采用改进的APINCH(抗菌素、钾及其他电解质、胰岛素、麻醉品及其他镇静剂、化疗药物、肝素及其他抗凝剂)分类系统来识别高危差错。测量了进行干预所需的时间,并收集了任何建议的详细信息。该研究包括22名干预患者和31名对照患者。接受干预的患者在DS中出现一种或多种药物错误的可能性较低(任何:4% vs 84%, p < 0.01;高风险:0% vs 29%, p < 0.01)。实习药师在干预期间共提出77条建议。6项建议(8%)与高危药物有关。进行第一次审查所需的中位数时间是4分钟,第二次审查需要1分钟。综上所述,我们发现有实习药师参与的调解干预可以降低DSs的用药错误率。
{"title":"Improving medicine information on discharge summaries through implementation of a reconciliation-based intervention","authors":"Anna Nguyen BPharm (Hons), GradCertPharmPrac,&nbsp;Stephanie Gibson BPharm (Hons), MClinPharm,&nbsp;Paul Wembridge BPharm (Hons), MClinPharm","doi":"10.1002/jppr.1828","DOIUrl":"10.1002/jppr.1828","url":null,"abstract":"<p>The handover of medication-related information at the point of discharge often occurs via the discharge summary (DS), although these frequently contain errors. We aimed to investigate whether an intern pharmacist reviewing the medication details in discharge summaries (DSs), reconciling them with the discharge prescription and pointing out any discrepancies with the medical staff would reduce the rate of medication errors. The intervention was retrospectively reviewed by comparing medication information on the DS with the discharge prescription (considered the ‘source of truth’). Error rates on the DS were compared to a control group of patients discharged over a different 2-week period from the same ward. A modified APINCH (Antimicrobials, Potassium and other electrolytes, Insulin, Narcotics and other sedatives, Chemotherapeutic agents, Heparin and other anticoagulants, Systems) classification system was used to identify high-risk errors. The time taken to perform the intervention was measured and details of any recommendations collected. The study included 22 intervention patients and 31 control patients. Patients who received the intervention were less likely to have one or more medication errors on their DS (any: 4% vs 84%, p &lt; 0.01; high-risk: 0% vs 29%, p &lt; 0.01). The intern pharmacist made a total of 77 recommendations during the intervention. Six recommendations (8%) related to high-risk medications. The median time required to undertake the first review was 4 min, and the second review took 1 min. In conclusion, we found a reconciliation-based intervention involving an intern pharmacist could reduce the rate of medication errors on DSs.</p>","PeriodicalId":16795,"journal":{"name":"Journal of Pharmacy Practice and Research","volume":"52 6","pages":"454-457"},"PeriodicalIF":2.1,"publicationDate":"2022-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jppr.1828","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43848719","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
In response: A benchmarking scoping review of research output from hospital pharmacy departments in Australia 回应:对澳大利亚医院药学部门的研究成果进行基准范围审查
IF 2.1 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2022-09-16 DOI: 10.1002/jppr.1831
Rohan A. Elliott BPharm, BPharmSc(Hons), MClinPharm, PhD, FSHP, Simone E. Taylor BPharm, PharmD, GradCertClinResMeth
<p>To the Editor,</p><p>We read with interest the article by Penm et al.<span><sup>1</sup></span> describing a benchmarking scoping review of research output from principal referral hospital pharmacy departments in Australia. We support the notion that benchmarking research output may assist pharmacy departments to improve their research performance, which has the potential to benefit patients, staff, and the broader health system.<span><sup>1, 2</sup></span> For this to be effective, it is important that benchmarking data be as accurate as possible and presented in a way that enables pharmacy departments to compare themselves with departments in similarly sized health services. Here we propose some ideas that may improve these aspects for future benchmarking studies.</p><p>A limitation of the benchmarking study noted by its authors was that the search strategy would not have captured research articles where authors used the name of their local health network instead of the principal hospital in their affiliation.<span><sup>1</sup></span> We are concerned that this may have led to a significant under-estimation of pharmacy research output. This is especially likely in Victoria, where each of the principal referral hospitals is part of a health network with one pharmacy department operating across all hospitals in the network. For example, Austin Health has one pharmacy department across its three hospitals, including the principal referral hospital, Austin Hospital. Pharmacy staff rotate between, or work across, the three sites. Research projects often span multiple sites. The affiliation that staff usually use is ‘Pharmacy Department, Austin Health’. Over the 2018–2020 benchmarking study period, the Austin Health Pharmacy Department produced over 50 peer-reviewed research articles that would have met the review's inclusion criteria.<span><sup>3</sup></span></p><p>The affiliation search terms described in Appendix S1 of the benchmarking paper<span><sup>1</sup></span> are based on those used by the Australian Institute of Health and Welfare for principal referral hospitals, but they are not necessarily the affiliation terms used by pharmacy department–based authors. The search terms would have missed many articles from Victorian principal referral hospitals at Austin Health, Barwon Health, and Monash Health but would have captured articles from all hospitals within the Alfred, Royal Melbourne, and St Vincent's networks. Hence, the data cannot be used to accurately benchmark Victorian hospitals.</p><p>An approach that would ensure data are consistently captured for all principal referral hospitals is to contact each pharmacy department to verify the literature search results. Criteria for which articles are eligible from pharmacy departments that service secondary hospitals in addition to the principal hospital could be developed (e.g. the article must have been produced by one or more pharmacy department staff members who worked at the principal h
致编辑:我们饶有兴趣地阅读了Penm et al.1的文章,该文章描述了澳大利亚主要转诊医院药房研究成果的基准范围审查。我们支持这样一种观点,即对研究成果进行基准测试可以帮助药学部门提高他们的研究绩效,这有可能使患者、工作人员和更广泛的卫生系统受益。1,2为使其有效,重要的是基准数据尽可能准确,并以使药房部门能够将自己与类似规模的卫生服务部门进行比较的方式呈现。在这里,我们提出了一些可以改善这些方面的想法,为未来的基准研究。该研究的作者指出,基准研究的一个局限性是,搜索策略不会捕获作者使用其当地卫生网络而不是其所属主要医院名称的研究文章我们担心这可能导致对药学研究产出的严重低估。这在维多利亚州尤其可能,那里的每个主要转诊医院都是卫生网络的一部分,一个药房部门在网络中的所有医院中运作。例如,Austin Health在其三家医院(包括主要转诊医院Austin hospital)设有一个药房部门。药房工作人员轮流在这三个地点工作。研究项目通常跨越多个站点。员工通常使用的隶属关系是“Austin Health药房”。在2018-2020年的基准研究期间,奥斯汀健康药房部门发表了50多篇同行评议的研究文章,这些文章符合审查的纳入标准。3基准文件1附录S1中描述的隶属关系搜索词是基于澳大利亚卫生和福利研究所对主要转诊医院使用的隶属关系搜索词,但它们不一定是药学部门作者使用的隶属关系搜索词。搜索词可能会错过许多来自维多利亚时期主要转诊医院的文章,如奥斯汀健康、巴温健康和莫纳什健康,但会捕获阿尔弗雷德、皇家墨尔本和圣文森特网络内所有医院的文章。因此,这些数据不能用来准确地对维多利亚州的医院进行基准测试。确保所有主要转诊医院一致捕获数据的一种方法是联系每个药房以验证文献检索结果。除主要医院外,还为二级医院提供服务的药房部门的文章是否合格,可以制定标准(例如,文章必须由在主要医院工作的一名或多名药房工作人员制作)。另一种选择是扩大搜索范围,包括拥有主要转诊医院和单一药房的地方卫生网络。这与基准研究作者的目标是一致的,他们的目标是将重点放在有望获得最高研究产出的卫生服务上,并避免一些主要转诊医院的文章缺失。澳大利亚医院药剂师协会(SHPA)目录可用于确定哪些主要医院是拥有一个药房部门的保健网络的一部分(即有一名药房主任,例如维多利亚州的奥斯汀保健网和南澳大利亚州的北阿德莱德地方保健网)。4一些主要转诊医院比其他医院大,这将影响研究能力。根据与药房部门相关的医院或健康网络的规模进行调整,以这种方式报告数据可能会使比较更有效。例如,研究产出可以以每500个住院床位的出版物报告。一些州的主要转诊医院比其他州多(例如,新南威尔士州有11家,而澳大利亚首都地区、北部地区和塔斯马尼亚州各有一家)。根据该州主要转诊医院或床位的数量对Penm等人1表3中的数据进行标准化,也有助于进行有效的州间比较。我们赞赏基准文件的作者从事这项工作,并希望我们的意见可以为今后主要转诊医院的基准研究提供参考。为鼓励所有药房发表其研究成果,并使其能够以同类医院为基准,未来的研究也可包括非主要转诊医院。这封信不包含作者进行的任何涉及人类参与者的研究。
{"title":"In response: A benchmarking scoping review of research output from hospital pharmacy departments in Australia","authors":"Rohan A. Elliott BPharm, BPharmSc(Hons), MClinPharm, PhD, FSHP,&nbsp;Simone E. Taylor BPharm, PharmD, GradCertClinResMeth","doi":"10.1002/jppr.1831","DOIUrl":"10.1002/jppr.1831","url":null,"abstract":"&lt;p&gt;To the Editor,&lt;/p&gt;&lt;p&gt;We read with interest the article by Penm et al.&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; describing a benchmarking scoping review of research output from principal referral hospital pharmacy departments in Australia. We support the notion that benchmarking research output may assist pharmacy departments to improve their research performance, which has the potential to benefit patients, staff, and the broader health system.&lt;span&gt;&lt;sup&gt;1, 2&lt;/sup&gt;&lt;/span&gt; For this to be effective, it is important that benchmarking data be as accurate as possible and presented in a way that enables pharmacy departments to compare themselves with departments in similarly sized health services. Here we propose some ideas that may improve these aspects for future benchmarking studies.&lt;/p&gt;&lt;p&gt;A limitation of the benchmarking study noted by its authors was that the search strategy would not have captured research articles where authors used the name of their local health network instead of the principal hospital in their affiliation.&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; We are concerned that this may have led to a significant under-estimation of pharmacy research output. This is especially likely in Victoria, where each of the principal referral hospitals is part of a health network with one pharmacy department operating across all hospitals in the network. For example, Austin Health has one pharmacy department across its three hospitals, including the principal referral hospital, Austin Hospital. Pharmacy staff rotate between, or work across, the three sites. Research projects often span multiple sites. The affiliation that staff usually use is ‘Pharmacy Department, Austin Health’. Over the 2018–2020 benchmarking study period, the Austin Health Pharmacy Department produced over 50 peer-reviewed research articles that would have met the review's inclusion criteria.&lt;span&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;The affiliation search terms described in Appendix S1 of the benchmarking paper&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; are based on those used by the Australian Institute of Health and Welfare for principal referral hospitals, but they are not necessarily the affiliation terms used by pharmacy department–based authors. The search terms would have missed many articles from Victorian principal referral hospitals at Austin Health, Barwon Health, and Monash Health but would have captured articles from all hospitals within the Alfred, Royal Melbourne, and St Vincent's networks. Hence, the data cannot be used to accurately benchmark Victorian hospitals.&lt;/p&gt;&lt;p&gt;An approach that would ensure data are consistently captured for all principal referral hospitals is to contact each pharmacy department to verify the literature search results. Criteria for which articles are eligible from pharmacy departments that service secondary hospitals in addition to the principal hospital could be developed (e.g. the article must have been produced by one or more pharmacy department staff members who worked at the principal h","PeriodicalId":16795,"journal":{"name":"Journal of Pharmacy Practice and Research","volume":"52 5","pages":"404-405"},"PeriodicalIF":2.1,"publicationDate":"2022-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jppr.1831","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49154896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Safety and efficacy comparisons of rituximab biosimilars to the reference product in patients with cancer: a systematic meta-analysis review 利妥昔单抗生物类似药与参考产品在癌症患者中的安全性和有效性比较:一项系统荟萃分析综述
IF 2.1 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2022-09-12 DOI: 10.1002/jppr.1827
Nina K. Song BPharm (Hons), Hala Musa BSc (Hons), MSc, MPharm, Michael Soriano BS Pharmacy (PH), Mellissa Batger BSc, MPharm, Bryson Hawkins BPharm (Hons), Iqbal Ramzan Dip Pharmacy (NZ), MSc, PhD (USyd), David E. Hibbs BSc (Hons), PhD, Grad Cert Ed (Higher Ed), Jennifer A. Ong BPharm (Hons), PhD, Grad Cert Ed Studies(Higher Ed)

Aim

To compare the efficacy and safety of rituximab biosimilars to reference rituximab in patients with cancer.

Data Sources

A systematic review and meta-analysis was conducted in accordance with PRISMA guidelines. MEDLINE, EMBASE, and Cochrane Central databases were searched from inception to 12 January 2022 to obtain all randomised control trial (RCTs) reporting on the safety and efficacy outcomes of patients with cancer treated with rituximab biosimilars.

Study Selection

All RCTs comparing the reference rituximab with a biosimilar, conducted in inpatient and outpatient settings, were included in the systematic review.

Results

Twenty-nine RCTs were identified to report on patients treated with rituximab. The odds of achieving overall response rate in patients treated with a rituximab biosimilar compared to the reference over at least 24 weeks of treatment was 1.06 (95% confidence interval [CI] 0.88–1.26). The proportion of patients experiencing any treatment emergent adverse events were comparable between the two study arms (OR 1.20 [95% CI 0.98–1.49]).

Conclusion

Biosimilars for rituximab have comparable efficacy and safety profiles in treatment naïve patients; however, evidence for efficacy and safety of switching patients from reference biologic to biosimilar is lacking, and further research is required.

目的比较利妥昔单抗生物类似药与利妥昔单抗对照药在肿瘤患者中的疗效和安全性。根据PRISMA指南进行系统评价和荟萃分析。检索MEDLINE、EMBASE和Cochrane Central数据库,从建立到2022年1月12日,获取所有报告利妥昔单抗生物类似药治疗癌症患者安全性和有效性结果的随机对照试验(rct)。所有在住院和门诊环境中进行的比较参考利妥昔单抗和生物仿制药的随机对照试验都被纳入系统评价。结果29项随机对照试验报告了利妥昔单抗治疗的患者。与对照组相比,接受利妥昔单抗生物类似药治疗的患者在至少24周的治疗中获得总缓解率的几率为1.06(95%可信区间[CI] 0.88-1.26)。两个研究组中出现任何治疗紧急不良事件的患者比例具有可比性(OR 1.20 [95% CI 0.98-1.49])。结论利妥昔单抗生物仿制药治疗naïve患者具有相当的疗效和安全性;然而,缺乏将患者从参考生物制剂转为生物类似药的有效性和安全性的证据,需要进一步研究。
{"title":"Safety and efficacy comparisons of rituximab biosimilars to the reference product in patients with cancer: a systematic meta-analysis review","authors":"Nina K. Song BPharm (Hons),&nbsp;Hala Musa BSc (Hons), MSc, MPharm,&nbsp;Michael Soriano BS Pharmacy (PH),&nbsp;Mellissa Batger BSc, MPharm,&nbsp;Bryson Hawkins BPharm (Hons),&nbsp;Iqbal Ramzan Dip Pharmacy (NZ), MSc, PhD (USyd),&nbsp;David E. Hibbs BSc (Hons), PhD, Grad Cert Ed (Higher Ed),&nbsp;Jennifer A. Ong BPharm (Hons), PhD, Grad Cert Ed Studies(Higher Ed)","doi":"10.1002/jppr.1827","DOIUrl":"10.1002/jppr.1827","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>To compare the efficacy and safety of rituximab biosimilars to reference rituximab in patients with cancer.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Data Sources</h3>\u0000 \u0000 <p>A systematic review and meta-analysis was conducted in accordance with PRISMA guidelines. MEDLINE, EMBASE, and Cochrane Central databases were searched from inception to 12 January 2022 to obtain all randomised control trial (RCTs) reporting on the safety and efficacy outcomes of patients with cancer treated with rituximab biosimilars.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Study Selection</h3>\u0000 \u0000 <p>All RCTs comparing the reference rituximab with a biosimilar, conducted in inpatient and outpatient settings, were included in the systematic review.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Twenty-nine RCTs were identified to report on patients treated with rituximab. The odds of achieving overall response rate in patients treated with a rituximab biosimilar compared to the reference over at least 24 weeks of treatment was 1.06 (95% confidence interval [CI] 0.88–1.26). The proportion of patients experiencing any treatment emergent adverse events were comparable between the two study arms (OR 1.20 [95% CI 0.98–1.49]).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Biosimilars for rituximab have comparable efficacy and safety profiles in treatment naïve patients; however, evidence for efficacy and safety of switching patients from reference biologic to biosimilar is lacking, and further research is required.</p>\u0000 </section>\u0000 </div>","PeriodicalId":16795,"journal":{"name":"Journal of Pharmacy Practice and Research","volume":"52 5","pages":"332-356"},"PeriodicalIF":2.1,"publicationDate":"2022-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jppr.1827","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45992323","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Scoping research output from tertiary hospital pharmacy departments: suggestions for improvement 三级医院药剂科研究成果的界定:改进建议
IF 2.1 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2022-09-05 DOI: 10.1002/jppr.1830
Jeanie Misko B Pharm, PGDipPharm, M Pharm (Clin Pharm), PGDipOncol (Distinction), GradCertBus, GradCertHlthEcon (Distinction), FSHP, Matthew D. M. Rawlins B Pharm, MBA, MSHP, Barry Jenkins B Pharm, MSHP
<p>We read with great interest the benchmarking scoping review by Penm et al.<span><sup>1</sup></span> on research output from principal referral hospital pharmacy departments in Australia from 2018 to 2020. This review allows departments to compare their research output with others and encourages a strong research culture within hospital pharmacy departments.</p><p>The <i>Australian hospital peer groups</i><span><sup>2</sup></span> report published by the Australian Institute of Health and Welfare (AIHW) was used to determine which hospitals were classified as principal referral hospitals in the review, with principal referral hospitals defined as public acute hospitals providing a broad range of services with highly specialised service units and large patient volumes.<span><sup>2</sup></span> This report from 2015 remains the most recently published,<span><sup>3</sup></span> though at least two new tertiary hospitals have opened in Australia since 2015.<span><sup>4, 5</sup></span></p><p>Fiona Stanley Hospital (FSH) is a 783-bed public quaternary hospital, which became fully operational in February 2015. The hospital fulfils the AIHW definition of a principal referral hospital, though it was absent from the 2015 AIHW hospital peer groups listing. The pharmacy department at FSH is making an increasing contribution to the peer-reviewed biomedical literature across a range of clinical and operational disciplines. The AIHW data also list hospitals in Western Australia (WA) which had closed by 2015 (Royal Perth Hospital Shenton Park campus and Kaleeya Hospital), as well as others which have closed subsequently, either prior to or during the 2018–2020 research window examined (Swan District Hospital and Princess Margaret Hospital for Children).<span><sup>2</sup></span> Although this is a scoping review, the hospital landscape is rapidly evolving, and we would caution against using reports that are likely to be outdated for the purposes of benchmarking. FSH pharmacy research output was not included in the scoping review,<span><sup>1</sup></span> suggesting that a second source was not utilised to validate the principal referral hospitals which were operational during the 2018–2020 time period.</p><p>Using the methods detailed in the scoping review,<span><sup>1</sup></span> we assessed the research output for the FSH pharmacy department from 2018 to 2020. Nine unique articles were located (one clinical trial, five observational studies, and three case reports). Four (44%) of these articles had a member of the pharmacy department as the first author, and eight (89%) articles had at least one author with a university affiliation. This output reflected the findings of Penm et al., Australia-wide. Adding the FSH output to the primary count resulted in a total of 21 articles (7% of the national total) published by WA pharmacy departments between 2018 and 2020.</p><p>We acknowledge the difficulty in obtaining current lists of Australian hospitals experienced
我们非常感兴趣地阅读了Penm等人对2018年至2020年澳大利亚主要转诊医院药房研究成果的基准范围审查1。这一审查允许各部门将其研究成果与其他部门进行比较,并鼓励医院药学部门建立强大的研究文化。澳大利亚卫生和福利研究所(AIHW)发表的澳大利亚医院同行小组2报告被用来确定哪些医院在审查中被列为主要转诊医院,主要转诊医院被定义为提供广泛服务的公立急症医院,拥有高度专业化的服务单位和大量病人这份2015年的报告仍然是最新发布的3,尽管自2015年以来,澳大利亚至少开设了两家新的三级医院。5菲奥娜斯坦利医院(FSH)是一家拥有783张床位的公立四级医院,于2015年2月全面投入运营。该医院符合卫生保健研究所对主要转诊医院的定义,尽管它没有出现在卫生保健研究所2015年的医院同行名单中。FSH的药学系正在为一系列临床和操作学科的同行评议生物医学文献做出越来越大的贡献。AIHW的数据还列出了西澳大利亚州(WA)到2015年关闭的医院(皇家珀斯医院Shenton Park校区和Kaleeya医院),以及随后在2018-2020年研究窗口之前或期间关闭的其他医院(天鹅区医院和玛格丽特公主儿童医院)虽然这是一项范围审查,但医院的情况正在迅速发展,我们要提醒大家不要使用可能过时的报告来进行基准测试。FSH药学研究成果未包括在范围审查中,1表明未使用第二来源来验证2018-2020年期间运营的主要转诊医院。使用范围综述中详细介绍的方法1,我们评估了2018年至2020年FSH药房的研究产出。找到了9篇独特的文章(1篇临床试验、5篇观察性研究和3篇病例报告)。这些文章中有4篇(44%)的第一作者是药学部门的成员,8篇(89%)的文章至少有一名作者与大学有联系。这一结果反映了Penm等人在澳大利亚范围内的研究结果。将FSH产量添加到初级统计中,2018年至2020年,西澳药学部门共发表了21篇文章(占全国总量的7%)。我们承认,很难获得提交人目前在澳大利亚医院工作的名单。提高医院清单准确性的一种方法是使用更频繁更新的医院药房特有的额外目录,例如澳大利亚医院药剂师协会出版的《澳大利亚药品信息服务目录》或《医院药房目录》。这一措施,连同纳入儿科三级转诊机构,将进一步改善这一优秀举措的影响。所有列出的作者都遵守《华尔街日报》的作者身份政策。由于文章的性质,这封信不需要伦理批准。
{"title":"Scoping research output from tertiary hospital pharmacy departments: suggestions for improvement","authors":"Jeanie Misko B Pharm, PGDipPharm, M Pharm (Clin Pharm), PGDipOncol (Distinction), GradCertBus, GradCertHlthEcon (Distinction), FSHP,&nbsp;Matthew D. M. Rawlins B Pharm, MBA, MSHP,&nbsp;Barry Jenkins B Pharm, MSHP","doi":"10.1002/jppr.1830","DOIUrl":"10.1002/jppr.1830","url":null,"abstract":"&lt;p&gt;We read with great interest the benchmarking scoping review by Penm et al.&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; on research output from principal referral hospital pharmacy departments in Australia from 2018 to 2020. This review allows departments to compare their research output with others and encourages a strong research culture within hospital pharmacy departments.&lt;/p&gt;&lt;p&gt;The &lt;i&gt;Australian hospital peer groups&lt;/i&gt;&lt;span&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt; report published by the Australian Institute of Health and Welfare (AIHW) was used to determine which hospitals were classified as principal referral hospitals in the review, with principal referral hospitals defined as public acute hospitals providing a broad range of services with highly specialised service units and large patient volumes.&lt;span&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt; This report from 2015 remains the most recently published,&lt;span&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/span&gt; though at least two new tertiary hospitals have opened in Australia since 2015.&lt;span&gt;&lt;sup&gt;4, 5&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;Fiona Stanley Hospital (FSH) is a 783-bed public quaternary hospital, which became fully operational in February 2015. The hospital fulfils the AIHW definition of a principal referral hospital, though it was absent from the 2015 AIHW hospital peer groups listing. The pharmacy department at FSH is making an increasing contribution to the peer-reviewed biomedical literature across a range of clinical and operational disciplines. The AIHW data also list hospitals in Western Australia (WA) which had closed by 2015 (Royal Perth Hospital Shenton Park campus and Kaleeya Hospital), as well as others which have closed subsequently, either prior to or during the 2018–2020 research window examined (Swan District Hospital and Princess Margaret Hospital for Children).&lt;span&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt; Although this is a scoping review, the hospital landscape is rapidly evolving, and we would caution against using reports that are likely to be outdated for the purposes of benchmarking. FSH pharmacy research output was not included in the scoping review,&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; suggesting that a second source was not utilised to validate the principal referral hospitals which were operational during the 2018–2020 time period.&lt;/p&gt;&lt;p&gt;Using the methods detailed in the scoping review,&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; we assessed the research output for the FSH pharmacy department from 2018 to 2020. Nine unique articles were located (one clinical trial, five observational studies, and three case reports). Four (44%) of these articles had a member of the pharmacy department as the first author, and eight (89%) articles had at least one author with a university affiliation. This output reflected the findings of Penm et al., Australia-wide. Adding the FSH output to the primary count resulted in a total of 21 articles (7% of the national total) published by WA pharmacy departments between 2018 and 2020.&lt;/p&gt;&lt;p&gt;We acknowledge the difficulty in obtaining current lists of Australian hospitals experienced ","PeriodicalId":16795,"journal":{"name":"Journal of Pharmacy Practice and Research","volume":"52 5","pages":"402-403"},"PeriodicalIF":2.1,"publicationDate":"2022-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jppr.1830","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47331543","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
How is surgical antibiotic prophylaxis prescribed for open reduction internal fixation procedures by Australian orthopaedic surgeons? 澳大利亚骨科医生是如何在切开复位内固定手术中开抗生素预防处方的?
IF 2.1 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2022-08-27 DOI: 10.1002/jppr.1823
Sarah Hassan BPharm (Hons), Vincent Chan BSc (Hons), BPharm, MPH, PhD, GradCertAcadPrac, AACPA, Julie E. Stevens BSc, BPharm (Hons), PhD, Ieva Stupans BPharm (Hons), PhD, Juliette Gentle MBBS, FRACS (Orth)

Surgical antibiotic prophylaxis (SAP) reduces the risk of surgical site infections following open reduction internal fixation (ORIF) procedures. Current guidelines recommend the use of single-dose prophylaxis for ORIF procedures. It is known that adherence to SAP guidelines is suboptimal across multiple surgical disciplines, including orthopaedic surgery. The aim of this study was to identify how Australian orthopaedic surgeons self-report prescribing of SAP for ORIF of closed fractures and whether practice adheres to recommendations in the Therapeutic Guidelines: Antibiotic version 16. An online survey was distributed to Australian orthopaedic surgeons between August 2020 and February 2021. The survey consisted of 10 questions relating to SAP prescribing practice for ORIF of closed fractures, guideline awareness, and factors that influence prescribing. Twenty-two surgeons participated in the survey. All 22 surgeons reported prescribing the guideline-adherent agent cefazolin for ORIF procedures, with 68.2% (n = 15) prescribing the non-adherent agent clindamycin for patients with a severe penicillin allergy. Almost two-thirds of the surgeons (63.6%) prescribe postoperative antibiotics, with two postoperative doses the most common regimen (57.1%). Although 63.6% of surgeons were aware of guideline content, adherence to guidelines varied. Surgeons noted that multiple factors influence their prescribing practice, including knowledge gained from personal readings (77.3%), habits developed during training (68.2%), and discussion with colleagues (63.6%). Factors that influence SAP decision making for ORIF procedures are multifactorial, with variable levels of guideline adherence. This small cohort of surgeons commonly reported prescribing postoperative antibiotics. Further research is required to understand what influences SAP decision-making.

外科抗生素预防(SAP)降低切开复位内固定(ORIF)手术后手术部位感染的风险。目前的指南建议口服干扰素手术使用单剂量预防。众所周知,在包括矫形外科在内的多个外科学科中,遵守SAP指南是次优的。本研究的目的是确定澳大利亚骨科医生如何自我报告闭合性骨折ORIF的SAP处方,以及实践是否遵守《治疗指南:抗生素第16版》的建议。一项在线调查于2020年8月至2021年2月期间向澳大利亚整形外科医生分发。调查包括10个问题,涉及闭合性骨折ORIF的SAP处方实践、指南意识和影响处方的因素。22名外科医生参与了调查。所有22名外科医生均报告在ORIF手术中使用指南粘附剂头孢唑林,68.2% (n = 15)的医生对严重青霉素过敏的患者使用非粘附剂克林霉素。几乎三分之二的外科医生(63.6%)在术后开抗生素,最常见的方案是术后两次剂量(57.1%)。尽管63.6%的外科医生知道指南的内容,但对指南的遵守程度各不相同。外科医生指出,多种因素影响他们的处方实践,包括从个人阅读中获得的知识(77.3%),培训期间养成的习惯(68.2%)以及与同事的讨论(63.6%)。影响SAP对ORIF程序决策的因素是多因素的,具有不同程度的指南依从性。这一小群外科医生通常报告开术后抗生素。需要进一步的研究来了解影响SAP决策的因素。
{"title":"How is surgical antibiotic prophylaxis prescribed for open reduction internal fixation procedures by Australian orthopaedic surgeons?","authors":"Sarah Hassan BPharm (Hons),&nbsp;Vincent Chan BSc (Hons), BPharm, MPH, PhD, GradCertAcadPrac, AACPA,&nbsp;Julie E. Stevens BSc, BPharm (Hons), PhD,&nbsp;Ieva Stupans BPharm (Hons), PhD,&nbsp;Juliette Gentle MBBS, FRACS (Orth)","doi":"10.1002/jppr.1823","DOIUrl":"10.1002/jppr.1823","url":null,"abstract":"<p>Surgical antibiotic prophylaxis (SAP) reduces the risk of surgical site infections following open reduction internal fixation (ORIF) procedures. Current guidelines recommend the use of single-dose prophylaxis for ORIF procedures. It is known that adherence to SAP guidelines is suboptimal across multiple surgical disciplines, including orthopaedic surgery. The aim of this study was to identify how Australian orthopaedic surgeons self-report prescribing of SAP for ORIF of closed fractures and whether practice adheres to recommendations in the <i>Therapeutic Guidelines: Antibiotic</i> <i>version</i> <i>16</i>. An online survey was distributed to Australian orthopaedic surgeons between August 2020 and February 2021. The survey consisted of 10 questions relating to SAP prescribing practice for ORIF of closed fractures, guideline awareness, and factors that influence prescribing. Twenty-two surgeons participated in the survey. All 22 surgeons reported prescribing the guideline-adherent agent cefazolin for ORIF procedures, with 68.2% (<i>n</i> = 15) prescribing the non-adherent agent clindamycin for patients with a severe penicillin allergy. Almost two-thirds of the surgeons (63.6%) prescribe postoperative antibiotics, with two postoperative doses the most common regimen (57.1%). Although 63.6% of surgeons were aware of guideline content, adherence to guidelines varied. Surgeons noted that multiple factors influence their prescribing practice, including knowledge gained from personal readings (77.3%), habits developed during training (68.2%), and discussion with colleagues (63.6%). Factors that influence SAP decision making for ORIF procedures are multifactorial, with variable levels of guideline adherence. This small cohort of surgeons commonly reported prescribing postoperative antibiotics. Further research is required to understand what influences SAP decision-making.</p>","PeriodicalId":16795,"journal":{"name":"Journal of Pharmacy Practice and Research","volume":"52 5","pages":"378-382"},"PeriodicalIF":2.1,"publicationDate":"2022-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jppr.1823","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47317787","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Conformity of prescription medication labels with label format and content recommendations 处方药标签与标签格式和内容建议的一致性
IF 2.1 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2022-08-26 DOI: 10.1002/jppr.1824
Yeow Boon Oh BSc (Pharm) (Hons), Sumithra Devi Suppiah BSc, MPharm, Deborah Miao-Hui Chia BSc (Pharm) (Hons), MClin Pharm, BCGP, Yi Wen Tan BSocSci, Rahul Malhotra MBBS, MD, MPH

Background

Prescription medication labels (PMLs) are central in guiding patients to use their medications appropriately. For PMLs to achieve this purpose, their content must enable medication use as desired and be presented in a clear and legible manner.

Aim

This study assesses the extent to which the format and content of PMLs used in Singapore meet national and/or international recommendations, and if the extent varies across public and private healthcare institutions.

Method

The format and content variables of 113 PMLs were compared against published recommendations. Variability in the extent to which the format and content of PMLs met the recommendations across public and private institutions was assessed through the Chi-square test or Fisher's exact test.

Results

Less than 50% of the PMLs conformed with the format recommendations of printing instructions in sentence case (35.4%), and the content recommendations for providing drug–food administration instructions (45.3%), using specific dosing intervals for dosing instructions (21.2%), providing an expiry date (17.7%), and generating bilingual labels (5.3%). A higher proportion of private institution PMLs followed the format recommendations of printing instructions in sentence case (p = 0.004) and numeric characters for quantitative values (p = 0.003), and the content recommendations for providing drug indication (p < 0.001). In contrast, a higher proportion of public institution PMLs followed the content recommendations of using specific dosing intervals (p = 0.001), providing side effects/precautions (p = 0.003), and providing drug-food administration instructions (p = 0.021).

Conclusion

There is definite scope for improving the format and content of PMLs in Singapore. Future studies could explore the possible logistical, financial, and administrative reasons that contribute to PML variability across healthcare institutions.

处方药物标签(pml)是指导患者正确使用药物的核心。为了实现这一目的,pml的内容必须使药物使用成为可能,并以清晰易读的方式呈现。目的本研究评估新加坡使用的pml的格式和内容在多大程度上符合国家和/或国际建议,以及公立和私立医疗机构之间的程度是否不同。方法将113份pml的格式和内容变量与已发表的建议进行比较。通过卡方检验或Fisher精确检验来评估pml的格式和内容在多大程度上符合公立和私立机构的建议。结果符合句子case中印刷说明书格式建议(35.4%)的pml不到50%,符合药品食品使用说明书内容建议(45.3%)、给药说明书使用特定给药间隔(21.2%)、提供有效期(17.7%)和生成双语标签(5.3%)的pml不到50%。较高比例的私立医疗机构pml采用句子大小写格式(p = 0.004)和定量值数字字符格式(p = 0.003),以及提供药物指证的内容建议(p < 0.001)。相比之下,较高比例的公共机构pml遵循了使用特定给药间隔(p = 0.001)、提供副作用/注意事项(p = 0.003)和提供药物-食品给药说明(p = 0.021)的内容建议。结论新加坡pml的格式和内容有一定的改进空间。未来的研究可以探索可能的后勤、财务和行政原因,导致PML在医疗机构之间的差异。
{"title":"Conformity of prescription medication labels with label format and content recommendations","authors":"Yeow Boon Oh BSc (Pharm) (Hons),&nbsp;Sumithra Devi Suppiah BSc, MPharm,&nbsp;Deborah Miao-Hui Chia BSc (Pharm) (Hons), MClin Pharm, BCGP,&nbsp;Yi Wen Tan BSocSci,&nbsp;Rahul Malhotra MBBS, MD, MPH","doi":"10.1002/jppr.1824","DOIUrl":"10.1002/jppr.1824","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Prescription medication labels (PMLs) are central in guiding patients to use their medications appropriately. For PMLs to achieve this purpose, their content must enable medication use as desired and be presented in a clear and legible manner.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>This study assesses the extent to which the format and content of PMLs used in Singapore meet national and/or international recommendations, and if the extent varies across public and private healthcare institutions.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Method</h3>\u0000 \u0000 <p>The format and content variables of 113 PMLs were compared against published recommendations. Variability in the extent to which the format and content of PMLs met the recommendations across public and private institutions was assessed through the Chi-square test or Fisher's exact test.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Less than 50% of the PMLs conformed with the format recommendations of printing instructions in sentence case (35.4%), and the content recommendations for providing drug–food administration instructions (45.3%), using specific dosing intervals for dosing instructions (21.2%), providing an expiry date (17.7%), and generating bilingual labels (5.3%). A higher proportion of private institution PMLs followed the format recommendations of printing instructions in sentence case (p = 0.004) and numeric characters for quantitative values (p = 0.003), and the content recommendations for providing drug indication (p &lt; 0.001). In contrast, a higher proportion of public institution PMLs followed the content recommendations of using specific dosing intervals (p = 0.001), providing side effects/precautions (p = 0.003), and providing drug-food administration instructions (p = 0.021).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>There is definite scope for improving the format and content of PMLs in Singapore. Future studies could explore the possible logistical, financial, and administrative reasons that contribute to PML variability across healthcare institutions.</p>\u0000 </section>\u0000 </div>","PeriodicalId":16795,"journal":{"name":"Journal of Pharmacy Practice and Research","volume":"52 6","pages":"427-437"},"PeriodicalIF":2.1,"publicationDate":"2022-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44136435","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
期刊
Journal of Pharmacy Practice and Research
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1